Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA10 known ✓ | Q9GZZ6 | 12/20 | 0.50 |
| ▸ | CHRNA9 known ✓ | Q9UGM1 | 12/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 11/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18980917 | 0.92 | CHRNA7 (0.69) | CHRNA7CHRNA10CHRNA9CYP3A4ALOX15 | |
| SCHEMBL14066535 | 0.90 | CHRNA7 (0.86) | CHRNA7CHRNA10CHRNA9CYP3A4ALOX15 | |
| Bromide SCHEMBL18980912 | 0.88 | CHRNA7 (0.83) | CHRNA7CHRNA10CHRNA9CYP3A4ALOX15 | |
| Iodide SCHEMBL18980648 | 0.88 | CHRNA7 (0.83) | CHRNA7CHRNA10CHRNA9CYP3A4ALOX15 | |
| Hydrochloric Acid SCHEMBL18980891 | 0.88 | CHRNA7 (0.83) | CHRNA7CHRNA10CHRNA9CYP3A4ALOX15 | |
| Acetic Acid SCHEMBL18980645 | 0.86 | CHRNA7 (0.69) | CHRNA7CHRNA10CHRNA9CYP3A4ALOX15 | |
| SCHEMBL18980712 | 0.85 | CHRNA7 (0.64) | CHRNA7CHRNA10CHRNA9CYP3A4ALOX15 | |
| SCHEMBL10115432 | 0.83 | CHRNA7 (1.00) | CHRNA7CHRNA10CHRNA9CYP3A4ALOX15 | |
| SCHEMBL18980726 | 0.82 | CHRNA7 (0.59) | CHRNA7CHRNA10CHRNA9CYP3A4ALOX15 | |
| Iodide SCHEMBL17144605 | 0.80 | CHRNA7 (0.69) | CHRNA7CHRNA10CHRNA9CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3125903-B1 | METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER | UNIV LAVAL (CA) | 2018-12-19 | — | — | EP | disclosed |
| US-20180235978-A1 | METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER | UNIVERSITé LAVAL (CA) | 2018-08-23 | — | — | US | disclosed |
| US-9949984-B2 | Method for use of homopiperazinium compounds in the treatment of cancer | UNIVERSITé LAVAL (CA) | 2018-04-24 | — | — | US | disclosed |
| US-20170173040-A1 | METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER | UNIVERSITé LAVAL (CA) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173040-A1 | METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER | HCCS, XDH, XPA | CHRNA10 1486/4885CHRNA9 1050/4885CHRNA7 861/4885 |
| US-20180235978-A1 | METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER | MGMT, KAT5, KAT2B | CHRNA10 2552/4885CHRNA9 1642/4885CHRNA7 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.